Methods
Medical charts of 26 pts, 25 F, 1 M, mean age at SLE diagnosis 12.7 yrs (range 5-18), mean age at MMF starting 15.9 yrs (range 7.5-26.8), followed in Florence, Padua, and Messina, Italy, treated with MMF from 2004 to 2007, were retrospectively analyzed. Clinical and laboratory evaluation included: blood count, ESR, CRP, ANA, antidsDNA, LFT, coagulation, C4, renal function, Coombs' test, aCL, antiβ2GPI and LAC at baseline and every 6 months. Disease activity was monitored by the SLEDAI score. Treatment duration was 24 ± 14.8 months (range 2-52). MMF (1.5-2 g/day) was started due to steroid toxicity (n = 9 pts), CyA toxicity (n = 5), disease activity (n = 8) or nephropathy progression despite previous immunosuppression (n = 4). 9/26 pts, before MMF had renal disease (7 WHO Class IIb, 1 Class III, 1 Class IV). In 5/9 MMF was the first treatment, while 4/9 had received immunosuppressants.
Results
MMF was effective in reducing disease activity, steroid sparing in 14/26 (54%), stabilizing the disease in 8 (31%) and ineffective in 4 (15%). In 9/13 (69%) without renal involvement a good response was registered. Among pts with renal involvement, MMF was effective in 5/13 (38%), partially effective in 4 (31%) and ineffective in 4 (31%). 2 pts stopped MMF for diarrhoea and abdominal pain.
Conclusion
MMF seems to be effective and safe in jo-SLE, especially in patients without renal involvement. SLEDAI scores were significantly reduced at 6 and 12 months; p < 0.05. from 15 th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14-17 September 2008
